Boehringer Ingelheim
Boehringer Ingelheim is a global pharmaceutical company based in Ingelheim am Rhein, Germany, with a focus on improving patient care through innovation. Established in 2010, the Boehringer Ingelheim Venture Fund specializes in early-stage investments in life sciences, biotechnology, and digital health. The fund targets groundbreaking therapeutics and novel technologies, emphasizing areas such as immuno-oncology, regenerative medicine, and disease-related biomarkers. It typically invests up to €15 million over the lifetime of a company, with a specific focus on North America and Europe/Israel. Boehringer Ingelheim's commitment to advancing biomedical research aims to enhance patient outcomes through pioneering science and the development of new therapeutic concepts.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of bacteria-based therapies specifically designed for cancer treatment. Recognizing the ongoing need for innovative solutions in oncology, T3 Pharmaceuticals aims to enhance the lives of cancer patients by creating highly specific and efficient treatments using live bacteria. Through its work, the company seeks to address the limitations of conventional therapies and contribute to the advancement of novel cancer medicines.
Actym is a biotechnology company that focuses on developing an immuno-oncology platform. It specializes in the fields of medical device, manufacturing, and distribution. It focuses on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor.
It was founded in 2017 and headquartered in San Francisco, California.
T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of bacteria-based therapies specifically designed for cancer treatment. Recognizing the ongoing need for innovative solutions in oncology, T3 Pharmaceuticals aims to enhance the lives of cancer patients by creating highly specific and efficient treatments using live bacteria. Through its work, the company seeks to address the limitations of conventional therapies and contribute to the advancement of novel cancer medicines.
Tacalyx GmbH operates as an oncology company, which focuses on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer. It provides technology platform for TACAs as novel targets for cancer therapy. The company is based in Berlin, Germany.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.